Why the study?
Are changes in echocardiographic parameters like volumes, strain, and ventricular-arterial coupling associated with LVEF declines in breast cancer patients treated with doxorubicin and trastuzumab?
Are changes in echocardiographic parameters like volumes, strain, and ventricular-arterial coupling associated with LVEF declines in breast cancer patients treated with doxorubicin and trastuzumab?
Detailed echocardiographic phenotyping, including strain and ventricular-arterial coupling, tracks with LVEF decline and recovery in breast cancer patients undergoing cardiotoxic chemotherapy.
May aid cardiotoxicity monitoring via strain and coupling; hypothesis-generating for prospective validation in breast cancer.
Doxorubicin and trastuzumab resulted in modest, persistent declines in LVEF at 3 years. Changes in volumes, strain, and ventricular-arterial coupling were consistently associated with concurrent and subsequent LVEF declines and recovery across therapies.
No takes yet. Share an insight, caveat, or question.
Narayan et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: